Labor Day in the United States pushed this issue back a day. Short week, full lineup.
The theme this week is follow-through. Almost every story is the second chapter of something you already read: a cyberattack that was “contained” and is now a guidance cut, a $13.1 billion acquisition whose brand is being retired, a plant bought out of a competitor’s collapse that’s now closing, a spinout that has stopped being a spinout and started being a company. The announcement is never the story. What the company does eleven days, or two years, later is.
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
8 things to watch this week:
1. 🔐 Boston Scientific says the cyberattack will hit Q3 and full-year results
A September 7 SEC filing says last month’s attack is “likely to have a material impact” on Q3 and full-year 2026, and that both guidance ranges are now “unlikely.” Manufacturing and shipping are largely restored, but the backlog will take time and only “some portion” of lost revenue will be recovered. Stryker held full-year guidance through its March attack; Boston Scientific is the first large-cap this year to concede the year to a breach — in a week that also brought a recall of Infinion CX spinal cord stimulator leads tied to 1,081 serious injuries.
Fierce Biotech
2. 🧭 Most device companies don’t fail on technology. They fail on sequencing.
The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.
Sponsored by RŌG Health
3. 🦾 Stryker signs a definitive agreement to acquire ZuriMED
Stryker is buying privately held ZuriMED and its commercialized FiberLocker System, which anchors a rotator cuff patch across the full patch-tendon interface rather than at suture points. Terms weren’t disclosed. This is a failure-mode acquisition, not a category acquisition: the target is the re-tear, and the product rides surgeon relationships Stryker already has. That’s the tuck-in profile every strategic says it wants.
Stryker
4. 💉 MiniMed files its first patch pump with the FDA and raises guidance
The Medtronic spinout posted Q1 revenue of $843 million, up 17%, raised full-year organic growth to 10.5%, and disclosed an FDA submission for MiniMed Fit — a tubeless pump with a 300-unit reservoir and up to seven days of wear, targeted for next summer — alongside completed pivotal enrollment for a fully closed-loop algorithm and CE mark for Flex. Read the Fit specs against Insulet: reservoir size and wear time are aimed at Type 2 patients on higher insulin volumes, where Omnipod’s lead is most exposed.
MedTech Dive
5. 🏷️ J&J MedTech is retiring the Shockwave Medical name
Effective October 1, Shockwave Medical becomes Johnson & Johnson MedTech and its IVL portfolio becomes “circulatory restoration solutions”; the name survives only on the products. J&J paid $13.1 billion in May 2024. Twenty-eight months is the shelf life of a category-defining brand inside the world’s second-largest device company. If you’re negotiating a sale and telling yourself the acquirer will “keep the brand,” this is what that looks like.
MassDevice
6. 🩻 GE HealthCare secures CE mark for Photonova Spectra photon-counting CT
The CE mark follows FDA clearance and Japanese approval in March, opening Europe for GE’s Deep Silicon detector platform. Silicon is the wager: a different detector material to differentiate in a segment Siemens has owned since the first photon-counting clearance in 2021. Three major markets in six months is the cadence of a company making up for arriving late.
Medical Device Network
7. ⚡ Abbott wins FDA approval for its dual-energy TactiFlex Duo ablation catheter
Duo delivers pulsed field and radiofrequency energy from one catheter, switchable mid-procedure; U.S. cases begin in the coming weeks. CEO Robert Ford has said Duo and Volt are the two products Abbott is counting on to regain EP share in the back half. J&J’s dual-energy catheter was approved in July, so the market has moved past “PFA or not” to “how many energies per catheter.” Single-modality PFA entrants now have a spec-sheet problem.
MedTech Dive
8. 🏭 Zoll is closing the California ventilator plant it bought from Vyaire
Zoll, part of Asahi Kasei, is shutting the Palm Springs plant it acquired in 2024 with select Vyaire ventilator assets; a WARN notice lists 78 employees affected. Two years is roughly how long the integration math on a distressed-asset deal takes to resolve, and it usually resolves toward the acquirer’s existing footprint. In a carve-out, the site is rarely part of what’s being bought.
MassDevice
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.
The dual-energy catheter is the one I keep coming back to here. Once both modalities live on the same device, “PFA versus RF” becomes a much less useful question than when the operator actually switches between them and whether that changes outcomes. I’d love to see real-world data on how often physicians use both energies in the same case once the novelty wears off.